| Title: |
Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study |
| Authors: |
Kovari, Helen; Sabin, Caroline A.; Ledergerber, Bruno; Ryom, Lene; Reiss, Peter; Law, Matthew; Pradier, Christian; Dabis, Francois; d'Arminio Monforte, Antonella; Smith, Colette; de Wit, Stephane; Kirk, Ole; Lundgren, Jens D.; Weber, Rainer; Powderly, B.; Shortman, N.; Moecklinghoff, C.; Reilly, G.; Franquet, X.; Hatleberg, C.I.; Ryom, L.; Sabin, C.A.; Kamara, D.; Smith, C.; Phillips, A.; Mocroft, A.; Bojesen, A.; Nielsen, J.; Matthews, C.; Raben, D.; Lundgren, J.D.; Salbøl Brandt, R.; Rickenbach, M.; Fanti, I.; Krum, E.; Hillebregt, M.; Geffard, S.; Mourabi, Jaohar; Sundström, A.; Delforge, M.; Fontas, E.; Torres, F.; McManus, H.; Wright, S.; Kjær, J.; Sjøl, A.; Meidahl, P.; Helweg-Larsen, J.; Schmidt Iversen, J. |
| Contributors: |
Highly Active Antiretroviral Therapy Oversight Committee; AbbVie, Bristol-Myers Squibb, Gilead Sciences Inc.; ViiV Healthcare; Merck & Co Inc.; Janssen Pharmaceuticals; Danish National Research Foundation; (; Dutch Ministry of Health, Welfare and Spor; Agence; Nationale de; Recherches sur le; SIDA; et les; Hépatites; Virales; National Institutes of Health's; National Institute of Allergy and Infectious Diseases; Merck Sharp & Dohme; Gilead Sciences; Bristol-Myers Squibb; Boehringer Ingelheim Roche; Pfizer; GlaxoSmithKline; Fondo de Investigación Sanitaria; Fundación para la Investigación y la Prevención del SIDA en Espanã; National Institutes of Health; BIOMED 1; BIOMED 2; 5th Framework Program; 6th Framework; Program; 7th Framework; Janssen R&D, Merck and Co. Inc., Pfizer Inc., GlaxoSmithKline LLC; The Swiss National Science Foundation; AbbVie; Janssen Pharmaceuticals to the Italian Cohort Naive to Antiretrovirals (The ICONA Foundation); Swiss National Science Foundation |
| Source: |
Open Forum Infectious Diseases ; volume 3, issue 1 ; ISSN 2328-8957 |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2016 |
| Description: |
Background. Although human immunodeficiency virus (HIV)-positive persons on antiretroviral therapy (ART) frequently have chronic liver enzyme elevation (cLEE), the underlying cause is often unclear. Methods. Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study participants without chronic viral hepatitis were observed to the earliest of cLEE (elevated aminotransferase ≥6 months), death, last follow-up, or January 2, 2014. Antiretroviral treatment exposure was categorized as follows: no exposure and ongoing short- and long-term exposure ( |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/ofid/ofw009 |
| Availability: |
https://doi.org/10.1093/ofid/ofw009; http://academic.oup.com/ofid/article-pdf/3/1/ofw009/33599960/ofw009.pdf |
| Rights: |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Accession Number: |
edsbas.C46C14A2 |
| Database: |
BASE |